Atherosclerosis
Volume 183, Issue 1 , Pages 65-73 , November 2005

S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits

Received 17 December 2004 ,Revised 22 February 2005 ,Accepted 25 February 2005.

References 

  1. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis. Evolving Concepts Circ. 1990;82:47–59
  2. Garcia Palmieri MR. The endothelium in health and in cardiovascular disease. P R Health Sci J. 1997;16:136–141
  3. Ip JH, Fuster V, Israel D, et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17:77b–88b
  4. Carter AJ, Bailey L, Devries J, Hubbard B. The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima after coronary stent placement in a novel diabetic porcine model of restenosis. Coron Artery Dis. 2000;11:473–479
  5. Antithrombotic-Trialists’-Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  6. Aronow WS. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease. Drugs Aging. 1999;15:91–101
  7. Smith WL, Meade EA, DeWitt DL, et al. Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994;744:50–57
  8. Hankey GJ. Current oral antiplatelet agents to prevent atherothrombosis. Cerebrovasc Dis. 2001;(11 Suppl 2):11–17
  9. Henriksson P, Hamberg M, Diczfalusy U. Formation of 15-HETE as a major hydroxyeicosatetraenoic acid in the atherosclerotic vessel wall. Biochim Biophys Acta. 1985;834:272–274
  10. Csiszar A, Stef G, Pacher P, Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids. 2002;66:557–558
  11. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood. 2000;96:3823–3826
  12. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?. Circulation. 2002;105:1620–1622
  13. Pfister SL, Schmitz JM, Willerson JT, Campbell WB. Characterization of arachidonic acid metabolism in Watanabe heritable hyperlipidemic (WHHL) and New Zealand white (NZW) rabbit aortas. Prostaglandins. 1988;36:515–532
  14. Ishizuka T, Kawakami M, Hidaka T, et al. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol. 1998;112:464–470
  15. Patrono C. Aspirin resistance: definition, mechanisms and clinical readouts. J Thromb Hemost. 2003;1:1710–1713
  16. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667–1672
  17. Verbeuren TJ, Simonet S, Descombes JJ, Cohen RA, Lavielle G. Pharmacology of S 18886 a new potent, long acting, orally active TP-receptor antagonist 2nd European congress of pharmacology. Budapest, Hungary. Fundam Clin Pharmacol. 1999;
  18. Yang D, Levens N, Zhang JN, Vanhoutte PM, Félétou M. Specific potentiation of endothelium-dependent contractions in SHR by tetrahydrobiopterin. Hypertension. 2003;41:136–142
  19. Belhassen L, Pelle G, Dubois-Rande J-L, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol. 2003;41:1198–1204
  20. Cayatte AJ, Du Y, Oliver Krasinski J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:1724–1728
  21. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539–541
  22. Caplice NM, Fennessy PA, Manderson JA, Campbell GR, Campbell JH. Rabbit models of atherosclerosis and restenosis. In:  Woodford FP,  Davignon J,  Sniderman A editor. Atherosclerosis X. Amsterdam: Elsevier; 1995;
  23. Rolfe BE, Stamatiou S, World CJ, et al. Leukaemia inhibitory factor retards the progression of atherosclerosis. Cardiovasc Res. 2003;58:222–230
  24. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 1999;85:199–207
  25. Taubman MB, Fallon JT, Schecter AD, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 1997;78:200–204
  26. Barnes SE, Weinberg PD. Contrasting patterns of spontaneous aortic disease in young and old rabbits. Arterioscler Thromb Vasc Biol. 1998;18:300–308
  27. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–1275
  28. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330–335
  29. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503–2509
  30. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 1997;49:15–19
  31. Rolfe BE, Muddiman JD, Smith NJ, Campbell GR, Campbell JH. ICAM-1 expression by vascular smooth muscle cells is phenotype-dependent. Atherosclerosis. 2000;149:99–110

PII: S0021-9150(05)00198-X

doi: 10.1016/j.atherosclerosis.2005.02.034

Atherosclerosis
Volume 183, Issue 1 , Pages 65-73 , November 2005

Article Tools

* Image Usage & Resolution